<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03246386</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF-17.08</org_study_id>
    <nct_id>NCT03246386</nct_id>
  </id_info>
  <brief_title>Dosing Obese With Noxafil® Under a Trial (DONUT)</brief_title>
  <acronym>DONUT</acronym>
  <official_title>Pharmacokinetics of Posaconazole Given as a Single Intravenous Dose to Obese Subjects: Dosing Obese With Noxafil® Under a Trial (DONUT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although posaconazole is approved for the prophylaxes and treatment of invasive fungal&#xD;
      infections, specific dosing guidelines for posaconazole in (morbidly) obese patients are not&#xD;
      specified. There is clear evidence indicating that heavier patients are receiving a&#xD;
      sub-optimal dose if the current guidelines are used. Specifically in the setting of augmented&#xD;
      prevalence of species with intermediate susceptible to posaconazole, adequate dosing is&#xD;
      needed at start of treatment.&#xD;
&#xD;
      Therefore it seems prudent to conduct a trial in a cohort of obese patients who receive&#xD;
      posaconazole (300mg or 400mg) and define the pharmacokinetics. These will then be compared to&#xD;
      the pharmacokinetics in a normal-weight group receiving 300mg posaconazole.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obese patients with a BMI ≥ 35 kg/m2 undergoing endoscopic gastric bypass surgery will&#xD;
      receive a 300 mg or 400mg dose of posaconazole. A PK curve will be determined after&#xD;
      administration at t=0.45, 0.75, 1, 1.5, 2, 4, 8, 12, 24, and (if feasible) 48 hours post&#xD;
      infusion. Blood samples (4 mL) on PK days will be taken to obtain at least 2.0 mL of plasma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2017</start_date>
  <completion_date type="Actual">September 1, 2018</completion_date>
  <primary_completion_date type="Actual">September 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Comparing a 2 groups of obese subjects vs 1 group of non-obese subjects.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Posaconazole exposure</measure>
    <time_frame>Through study completion (usually after 24 or 48 hours)</time_frame>
    <description>The concentration-time curve of posaconazole in obese will be compared with that in non-obese subjects. Exposure is assessed by Area-Under-the-Curve from zero to 48 hours (AUC0-48h).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exposure with augemented posaconazol dose</measure>
    <time_frame>Through study completion (usually after 24 or 48 hours)</time_frame>
    <description>The concentration-time curve of posaconazole in obese receiving 400mg will be compared with that in non-obese subjects. Exposure is assessed by Area-Under-the-Curve from zero to 48 hours (AUC0-48h).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Obese subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with a BMI&gt;35 kg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-obese subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with a BMI&gt;18.5 and &lt;25 kg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole Injection [Noxafil] 300mg</intervention_name>
    <description>Single dose by intravenous infusion 300mg</description>
    <arm_group_label>Non-obese subjects</arm_group_label>
    <arm_group_label>Obese subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole Injection [Noxafil] 400mg</intervention_name>
    <description>Single dose by intravenous infusion 400mg</description>
    <arm_group_label>Obese subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects BMI:&#xD;
&#xD;
               -  obese groups: subject must have a BMI ≥35 kg/m2 at the time of inclusion,&#xD;
&#xD;
               -  non-obese group: subject must have a BMI ≥18.5 and &lt; 25kg/m2 at the time of&#xD;
                  inclusion.&#xD;
&#xD;
          2. Subject is at least 18 of age on the day of screening and not older than 65 years of&#xD;
             age on the day of dosing;&#xD;
&#xD;
          3. If a woman, is neither pregnant nor able to become pregnant and is not nursing an&#xD;
             infant;&#xD;
&#xD;
          4. Subject is able and willing to sign the Informed Consent before screening evaluations.&#xD;
&#xD;
             For the non-obese subjects the following additional inclusion criteria applies:&#xD;
&#xD;
          5. Subject is in good age-appropriate health condition as established by medical history,&#xD;
             physical examination, electrocardiography, results of biochemistry, hematology and&#xD;
             urinalysis testing within 6 weeks prior to study drug administration. Results of&#xD;
             biochemistry, hematology and urinalysis testing should be within the laboratory's&#xD;
             reference ranges (see Appendix A). If laboratory results are not within the reference&#xD;
             ranges, the subject is included based on the investigator's judgment that the observed&#xD;
             deviations are not clinically relevant. This should be clearly recorded;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documented history of sensitivity to medicinal products or excipients similar to those&#xD;
             found in the posaconazole preparation;&#xD;
&#xD;
          2. History of, or known abuse of drugs, alcohol or solvents (up until a maximum of three&#xD;
             months before study drug administration);&#xD;
&#xD;
          3. Use of medication that has known relevant interaction with study drug as determined by&#xD;
             the investigator up to 1 weeks prior to study drug administration.&#xD;
&#xD;
          4. Donation of blood or plasma to a blood bank or in a clinical study (except a screening&#xD;
             visit) within 4 weeks prior to study drug administration;&#xD;
&#xD;
          5. Blood transfusion within 8 weeks prior to study drug administration;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Brüggemann, PhD-PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Antonius hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/31971567/</url>
    <description>paper</description>
  </link>
  <results_reference>
    <citation>Wasmann RE, Smit C, van Donselaar MH, van Dongen EPA, Wiezer RMJ, Verweij PE, Burger DM, Knibbe CAJ, Brüggemann RJM. Implications for IV posaconazole dosing in the era of obesity. J Antimicrob Chemother. 2020 Apr 1;75(4):1006-1013. doi: 10.1093/jac/dkz546.</citation>
    <PMID>31971567</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2017</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

